Tellioglu T, Robertson D (November 2001). "Genetic or acquired deficits in the norepinephrine transporter: current understanding of clinical implications". Expert Reviews in Molecular Medicine. 2001 (29): 1–10. doi:10.1017/S1462399401003878. PMID14987367. S2CID30965333.
Kim JW, Biederman J, McGrath CL, Doyle AE, Mick E, Fagerness J, Purcell S, Smoller JW, Sklar P, Faraone SV (June 2008). "Further evidence of association between two NET single-nucleotide polymorphisms with ADHD". Molecular Psychiatry. 13 (6): 624–30. doi:10.1038/sj.mp.4002090. PMID17876324. S2CID8341997.
Esler M, Alvarenga M, Pier C, Richards J, El-Osta A, Barton D, Haikerwal D, Kaye D, Schlaich M, Guo L, Jennings G, Socratous F, Lambert G (July 2006). "The neuronal noradrenaline transporter, anxiety and cardiovascular disease". Journal of Psychopharmacology. 20 (4 Suppl): 60–6. doi:10.1177/1359786806066055. PMID16785272. S2CID10728780.
Stöber G, Nöthen MM, Pörzgen P, Brüss M, Bönisch H, Knapp M, Beckmann H, Propping P (November 1996). "Systematic search for variation in the human norepinephrine transporter gene: identification of five naturally occurring missense mutations and study of association with major psychiatric disorders". American Journal of Medical Genetics. 67 (6): 523–32. doi:10.1002/(SICI)1096-8628(19961122)67:6<523::AID-AJMG3>3.0.CO;2-I. PMID8950409.
Sager JJ, Torres GE (August 2011). "Proteins interacting with monoamine transporters: current state and future challenges". Biochemistry. 50 (34): 7295–310. doi:10.1021/bi200405c. PMID21797260.
Galli A, DeFelice LJ, Duke BJ, Moore KR, Blakely RD (October 1995). "Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants". The Journal of Experimental Biology. 198 (Pt 10): 2197–212. doi:10.1242/jeb.198.10.2197. PMID7500004.
Gether U, Andersen PH, Larsson OM, Schousboe A (July 2006). "Neurotransmitter transporters: molecular function of important drug targets". Trends in Pharmacological Sciences. 27 (7): 375–83. doi:10.1016/j.tips.2006.05.003. PMID16762425.
Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, Huwyler J, Liechti ME (August 2011). "The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans". Clinical Pharmacology and Therapeutics. 90 (2): 246–55. doi:10.1038/clpt.2011.78. PMID21677639. S2CID29087593.
Breier A, Wolkowitz OM, Roy A, Potter WZ, Pickar D (November 1990). "Plasma norepinephrine in chronic schizophrenia". The American Journal of Psychiatry. 147 (11): 1467–70. doi:10.1176/ajp.147.11.1467. PMID2221157.
Sternberg DE, Charney DS, Heninger GR, Leckman JF, Hafstad KM, Landis DH (March 1982). "Impaired presynaptic regulation of norepinephrine in schizophrenia. Effects of clonidine in schizophrenic patients and normal controls". Archives of General Psychiatry. 39 (3): 285–9. doi:10.1001/archpsyc.1982.04290030025004. PMID6279049.
van Kammen DP, Antelman S (April 1984). "Impaired noradrenergic transmission in schizophrenia?". Life Sciences. 34 (15): 1403–13. doi:10.1016/0024-3205(84)90054-7. PMID6323903.
Tellioglu T, Robertson D (November 2001). "Genetic or acquired deficits in the norepinephrine transporter: current understanding of clinical implications". Expert Reviews in Molecular Medicine. 2001 (29): 1–10. doi:10.1017/S1462399401003878. PMID14987367. S2CID30965333.
Kim JW, Biederman J, McGrath CL, Doyle AE, Mick E, Fagerness J, Purcell S, Smoller JW, Sklar P, Faraone SV (June 2008). "Further evidence of association between two NET single-nucleotide polymorphisms with ADHD". Molecular Psychiatry. 13 (6): 624–30. doi:10.1038/sj.mp.4002090. PMID17876324. S2CID8341997.
Esler M, Alvarenga M, Pier C, Richards J, El-Osta A, Barton D, Haikerwal D, Kaye D, Schlaich M, Guo L, Jennings G, Socratous F, Lambert G (July 2006). "The neuronal noradrenaline transporter, anxiety and cardiovascular disease". Journal of Psychopharmacology. 20 (4 Suppl): 60–6. doi:10.1177/1359786806066055. PMID16785272. S2CID10728780.
Stöber G, Nöthen MM, Pörzgen P, Brüss M, Bönisch H, Knapp M, Beckmann H, Propping P (November 1996). "Systematic search for variation in the human norepinephrine transporter gene: identification of five naturally occurring missense mutations and study of association with major psychiatric disorders". American Journal of Medical Genetics. 67 (6): 523–32. doi:10.1002/(SICI)1096-8628(19961122)67:6<523::AID-AJMG3>3.0.CO;2-I. PMID8950409.
Sager JJ, Torres GE (August 2011). "Proteins interacting with monoamine transporters: current state and future challenges". Biochemistry. 50 (34): 7295–310. doi:10.1021/bi200405c. PMID21797260.
Galli A, DeFelice LJ, Duke BJ, Moore KR, Blakely RD (October 1995). "Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants". The Journal of Experimental Biology. 198 (Pt 10): 2197–212. doi:10.1242/jeb.198.10.2197. PMID7500004.
Gether U, Andersen PH, Larsson OM, Schousboe A (July 2006). "Neurotransmitter transporters: molecular function of important drug targets". Trends in Pharmacological Sciences. 27 (7): 375–83. doi:10.1016/j.tips.2006.05.003. PMID16762425.
Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, Huwyler J, Liechti ME (August 2011). "The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans". Clinical Pharmacology and Therapeutics. 90 (2): 246–55. doi:10.1038/clpt.2011.78. PMID21677639. S2CID29087593.
Breier A, Wolkowitz OM, Roy A, Potter WZ, Pickar D (November 1990). "Plasma norepinephrine in chronic schizophrenia". The American Journal of Psychiatry. 147 (11): 1467–70. doi:10.1176/ajp.147.11.1467. PMID2221157.
Sternberg DE, Charney DS, Heninger GR, Leckman JF, Hafstad KM, Landis DH (March 1982). "Impaired presynaptic regulation of norepinephrine in schizophrenia. Effects of clonidine in schizophrenic patients and normal controls". Archives of General Psychiatry. 39 (3): 285–9. doi:10.1001/archpsyc.1982.04290030025004. PMID6279049.
van Kammen DP, Antelman S (April 1984). "Impaired noradrenergic transmission in schizophrenia?". Life Sciences. 34 (15): 1403–13. doi:10.1016/0024-3205(84)90054-7. PMID6323903.
Tellioglu T, Robertson D (November 2001). "Genetic or acquired deficits in the norepinephrine transporter: current understanding of clinical implications". Expert Reviews in Molecular Medicine. 2001 (29): 1–10. doi:10.1017/S1462399401003878. PMID14987367. S2CID30965333.
Kim JW, Biederman J, McGrath CL, Doyle AE, Mick E, Fagerness J, Purcell S, Smoller JW, Sklar P, Faraone SV (June 2008). "Further evidence of association between two NET single-nucleotide polymorphisms with ADHD". Molecular Psychiatry. 13 (6): 624–30. doi:10.1038/sj.mp.4002090. PMID17876324. S2CID8341997.
Esler M, Alvarenga M, Pier C, Richards J, El-Osta A, Barton D, Haikerwal D, Kaye D, Schlaich M, Guo L, Jennings G, Socratous F, Lambert G (July 2006). "The neuronal noradrenaline transporter, anxiety and cardiovascular disease". Journal of Psychopharmacology. 20 (4 Suppl): 60–6. doi:10.1177/1359786806066055. PMID16785272. S2CID10728780.